LIN SUE-JEAN 4

What Happened

• Lin Sue-Jean, a director of Arcutis Biotherapeutics (ARQT), sold 4,946 shares on June 15, 2026. The weighted average sale price was $24.38 per share, for total proceeds of approximately $120,587. The filing reports the transaction as a sale (S).

Key Details

• Transaction date and prices: June 15, 2026; weighted average price $24.38; individual sale prices ranged from $24.045 to $24.62.
• Transaction type/code: Open market/private sale (Code S).
• Shares owned after transaction: Not specified in the excerpt provided — consult the full Form 4 for post-transaction holdings.
• Footnotes: The sale was executed under a 10b5-1 trading plan adopted by Ms. Lin on December 4, 2025 (plan ends Feb 19, 2027). The filer notes the reported price is a weighted average and will provide a breakdown of shares sold at each price upon request.
• Filing timeliness: Reported on June 17, 2026 for a June 15, 2026 transaction — this appears to be a timely Form 4 filing.

Context

• The sale was made under a pre-established 10b5-1 trading plan, which typically means the trades were scheduled in advance and can help insulate the filer from insider trading concerns. Sales are common insider activity and, on their own, do not necessarily indicate negative views about the company.